Kazuko Saeki

Kazuko Saeki

Auto-generated profile, based on publicly available information

Kazuko Saeki

Department of Biochemistry Juntendo University School of Medicine Tokyo Japan

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2014 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
MLMin Liu
Min Liu
KSKazuko Saeki
Kazuko Saeki
TMTakehiko Matsunobu
Takehiko Matsunobu
TOToshiaki Okuno
Toshiaki Okuno
TKTomoaki Koga
Tomoaki Koga
TYTakehiko Yokomizo
Takehiko Yokomizo
Leukotriene B4 (LTB4) receptor type 2 (BLT2) is a G protein–coupled receptor (GPCR) for 12(S)-hydroxyheptadeca-5Z,8E,10E-trienoic acid (12-HHT) and LTB4. Despite the well-defined proinflammatory roles of BLT1, the in vivo functions of BLT2 remain elusive. As mouse BLT2 is highly expressed in epidermal keratinocytes, we investigated the role of the 12-HHT/BLT2 axis in skin wound healing processes. 12-HHT accumulated in the wound fluid in mice, and BLT2-deficient mice exhibited impaired re-epithelialization and delayed wound closure after skin punching. Aspirin administration reduced 12-HHT production and resulted in delayed wound closure in wild-type mice, which was abrogated in BLT2-deficient mice. In vitro scratch assay using primary keratinocytes and a keratinocyte cell line also showed that the 12-HHT/BLT2 axis accelerated wound closure through the production of tumor necrosis factor α (TNF) and matrix metalloproteinases (MMPs). A synthetic BLT2 agonist accelerated wound closure in cultured cells as well as in C57BL/6J and diabetic mice. These results identify a novel mechanism underlying the action of the 12-HHT/BLT2 axis in epidermal keratinocytes and accordingly suggest the use of BLT2 agonists as therapeutic agents to accelerate wound healing, particularly for intractable wounds, such as diabetic ulcers.

1 May 2016 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
MTMegumi Tatematsu
Megumi Tatematsu
RYRyuji Yoshida
Ryuji Yoshida
YMYuka Morioka
Yuka Morioka
NINoriko Ishii
Noriko Ishii
KFKenji Funami
Kenji Funami
MMMisako Matsumoto
Misako Matsumoto
The clathrin-dependent endocytic pathway is crucial for endosomal TLR3- and TLR4-mediated Toll–IL-1R domain–containing adaptor molecule-1 (TICAM-1) signaling. TLR4 uses a different signaling platform, plasma membrane and endosomes, for activation of TIRAP-MyD88 and TICAM-2–TICAM-1, respectively. LPS-induced endocytosis of TLR4 is mandatory for TICAM-1–mediated signaling including IFN-β production. Several molecules/mechanisms such as CD14, clathrin, and phosphatidylinositol metabolism have been reported to act as inducers of TLR4 translocation. However, the molecular mechanism of spatiotemporal regulation of TLR4 signaling remains unresolved. We have previously shown that Raftlin is essential for clathrin-dependent endocytosis of TLR3 ligand in human epithelial cells and myeloid dendritic cells (DCs). In this article, we demonstrate that Raftlin also mediated LPS-induced TLR4 internalization and TICAM-1 signaling in human monocyte-derived DCs and macrophages (Mo-Mϕs). When Raftlin was knocked down, LPS-induced TLR4-mediated IFN-β promoter activation, but not NF-κB activation, was decreased in HEK293 cells overexpressing TLR4/MD-2 or TLR4/MD-2/CD14. LPS-induced IFN-β production by monocyte-derived DCs and Mo-Mϕs was significantly decreased by knockdown of Raftlin. Upon LPS stimulation, Raftlin moved from the cytoplasm to the plasma membrane in Mo-Mϕs, where it colocalized with TLR4. Raftlin associated with clathrin-associated adaptor protein–2 in resting cells and transiently bound to TLR4 and clathrin at the cell surface in response to LPS. Thus, Raftlin appears to modulate cargo selection as an accessary protein of clathrin-associated adaptor protein–2 in clathrin-mediated endocytosis of TLR3/4 ligands.

13 June 2011 in Genes to Cells
Verified
Journal Article
Open access
PDF file
TITakuma Ishizaki
Takuma Ishizaki
TTTaiga Tamiya
Taiga Tamiya
KTKoji Taniguchi
Koji Taniguchi
RMRimpei Morita
Rimpei Morita
RKReiko Kato
Reiko Kato
AYAkihiko Yoshimura
Akihiko Yoshimura
The protein known as Spred1 (Sprouty‐related Ena/VASP homology‐1 domain‐containing protein) has been identified as a negative regulator of growth factor‐induced ERK/mitogen‐activated protein kinase activation. Spred1 has also been implicated as the target of microRNA‐126 (miR126), a miRNA located within the Egfl7 gene, and is involved in the regulation of vessel development through its role in regulating VEGF signaling. In this study, we examined the role of miR126 and Spred1 in the hematopoietic system, as miR126 has been shown to be overexpressed in leukemic cells. miR126 levels were down‐regulated during mast cell differentiation from bone marrow cells, whereas Spred1 expression was inversely up‐regulated. Overexpression of miR126 suppressed Spred1 expression and enhanced ERK activity in primary bone marrow cells and MC9 mast cells, which were associated with elevated FcεRI‐mediated cytokine production. To confirm the effect of Spred1 reduction in vivo, we generated hematopoietic cell‐specific Spred1‐conditional knockout mice. These mice showed increased numbers of mast cells, and Spred1‐deficient bone marrow‐derived mast cells were highly activated by cross‐linking of Fcε‐R stimulation as well as by IL‐3 and SCF stimulation. These results suggest that Spred1 negatively regulates mast cell activation, which is modulated by miR126.

2 November 2015 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
YIYumiko Ishii
Yumiko Ishii
KSKazuko Saeki
Kazuko Saeki
MLMin Liu
Min Liu
FSFumiyuki Sasaki
Fumiyuki Sasaki
TKTomoaki Koga
Tomoaki Koga
TYTakehiko Yokomizo
Takehiko Yokomizo
GPCRs are involved in numerous physiologic functions and are important drug targets. Although the epithelial barrier is important for protection from invading pathogens, the correlation between GPCRs and epithelial barrier function remains unknown. Leukotriene B 4 (LTB 4 ) receptor type 2 (BLT2), mainly expressed in epithelial cells, is a GPCR for 12( S )‐hydroxyheptadeca‐5 Z ,8 E ,10 E ‐trienoic acid (12‐HHT) and LTB 4 . In our study, BLT2 localized at the lateral membrane in BLT2‐overexpressing Madin‐Darby canine kidney (MDCK) II cells and in the small intestine of BLT2‐transgenic mice. BLT2‐deficient mice exhibited higher transepidermal water loss and were more sensitive to epicutaneous sensitization. MDCK‐BLT2 cells recovered transepithelial electrical resistance (TER) after a calcium switch faster than did MDCK‐Mock cells, and 12‐HHT stimulation accelerated TER recovery only in MDCK‐BLT2 cells. Quantitative PCR and immunoblot analyses revealed that the 12‐HHT/BLT2 axis up‐regulated claudin‐4 (CLDN4) expression in MDCK‐BLT2 cells and human primary keratinocytes, and CLDN4 knockdown abolished 12‐HHT‐dependent TER recovery. Acceleration of TER recovery and induction of CLDN4 expression by 12‐HHT stimulation were abolished by inhibition of Gα i protein or p38 MAPK. These results show that 12‐HHT/BLT2 enhances epithelial barrier function by increasing CLDN4 expression via the Gα i protein‐p38 MAPK pathway.—Ishii, Y., Saeki, K., Liu, M., Sasaki, F., Koga, T., Kitajima, K., Meno, C., Okuno, T., Yokomizo, T. Leukotriene B 4 receptor type 2 (BLT2) enhances skin barrier function by regulating tight junction proteins. FASEB J. 30, 933–947 (2016). www.fasebj.org

20 September 2018 in JCI Insight
Verified
Journal Article
Open access
PDF file
FSFumiyuki Sasaki
Fumiyuki Sasaki
TKTomoaki Koga
Tomoaki Koga
MOMai Ohba
Mai Ohba
KSKazuko Saeki
Kazuko Saeki
TOToshiaki Okuno
Toshiaki Okuno
TYTakehiko Yokomizo
Takehiko Yokomizo
Age-related macular degeneration (AMD), a progressive chronic disease of the central retina, is associated with aging and is a leading cause of blindness worldwide. Here, we demonstrate that leukotriene B 4 (LTB 4 ) receptor 1 (BLT1) promotes laser-induced choroidal neovascularization (CNV) in a mouse model for wet-type AMD. CNV was significantly less in BLT1-deficient (BLT1-KO) mice compared with BLT1-WT controls. Expression of several proangiogenic and profibrotic factors was lower in BLT1-KO eyes than in BLT1-WT eyes. LTB 4 production in the eyes was substantially increased in the early phase after laser injury. BLT1 was highly expressed in M2 macrophages in vitro and in vivo, and ocular BLT1 + M2 macrophages were increased in the aged eyes after laser injury. Furthermore, M2 macrophages were rapidly attracted by LTB 4 and subsequently produced VEGF-A– through BLT1-mediated signaling. Consequently, intravitreal injection of M2 macrophages augmented CNV formation, which was attenuated by BLT1 deficiency. Thus, laser-induced injury to the retina triggered LTB 4 production and attracted M2 macrophages via BLT1, leading to development of CNV. A selective BLT1 antagonist (CP105696) and 3 LTB 4 inhibitors (zileuton, MK-886, and bestatin) reduced CNV in a dose-dependent manner. CP105696 also inhibited the accumulation of BLT1 + M2 macrophages in the laser-injured eyes of aged mice. Together, these results indicate that the LTB 4 -BLT1 axis is a potentially novel therapeutic target for CNV of wet-type AMD.

1 October 2018 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
MOMai Ohba
Mai Ohba
KSKazuko Saeki
Kazuko Saeki
TKTomoaki Koga
Tomoaki Koga
TOToshiaki Okuno
Toshiaki Okuno
YKYuichi Kobayashi
Yuichi Kobayashi
TYTakehiko Yokomizo
Takehiko Yokomizo